Dr. David Russler-Germain, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Lymphoma
Studies Follicular Lymphoma
4 reported clinical trials
7 drugs studied
Area of expertise
1Lymphoma
Stage III
Stage IV
Stage II
2Follicular Lymphoma
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials David Russler-Germain, M.D., Ph.D. is currently running
Mosunetuzumab + Polatuzumab Vedotin
for Follicular Lymphoma
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to certain cancerous B cells and then delivers a drug specifically to those cells.
Recruiting2 awards Phase 2
Mosunetuzumab
for Aggressive B-Cell Lymphoma
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Recruiting2 awards Phase 1
More about David Russler-Germain, M.D., Ph.D.
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David Russler-Germain, M.D., Ph.D. has experience with
- Mosunetuzumab
- Polatuzumab Vedotin
- DHAX
- ICE
- Autologous Stem Cell Transplant
- Carmustine
Breakdown of trials David Russler-Germain, M.D., Ph.D. has run
Lymphoma
Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Russler-Germain, M.D., Ph.D. specialize in?
David Russler-Germain, M.D., Ph.D. focuses on Lymphoma and Follicular Lymphoma. In particular, much of their work with Lymphoma has involved Stage III patients, or patients who are Stage IV.
Is David Russler-Germain, M.D., Ph.D. currently recruiting for clinical trials?
Yes, David Russler-Germain, M.D., Ph.D. is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that David Russler-Germain, M.D., Ph.D. has studied deeply?
Yes, David Russler-Germain, M.D., Ph.D. has studied treatments such as Mosunetuzumab, Polatuzumab vedotin, DHAX.
What is the best way to schedule an appointment with David Russler-Germain, M.D., Ph.D.?
Apply for one of the trials that David Russler-Germain, M.D., Ph.D. is conducting.
What is the office address of David Russler-Germain, M.D., Ph.D.?
The office of David Russler-Germain, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.